



# Corporate Presentation

February 2024 | Nasdaq: BSGM



# BioSig Forward-Looking Statements

This presentation contains forward-looking statements including statements that address activities, events, or developments that BioSig expects, believes, or anticipates will or may occur in the future, such as predictions of financial performance, approvals, and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments, and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions, and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.



## Reimagining What's Possible in Cardiac Care



We are a medical technology company focused on deciphering and animating the body's electrical signals, starting with heart rhythms.



# The Market Dynamics



## Current market

33.5M people worldwide live with atrial fibrillation. Medicines, widely prescribed, are not curative and have side effects. There's an unmet need for alternative treatments, like catheter ablations.



## Cost Escalation

\$7B is invested by hospitals each year on capital equipment and high-cost catheters. The cost of delivering high-quality care to patients requires doing more with less—increasing pressure on physicians to find ways to improve procedural workflow.



## Procedural need

Better intracardiac signal quality could lead to improved success rates and ablation efficacy. Poor signal quality leads to more time in expensive EP labs. More precise signals are needed to diagnose and treat arrhythmias.



## Cost-saving solution

Our strategy is to deliver superior signal quality and contribute to greater procedural efficacy. Our subscription model removes the burden of ownership and maintenance for hospitals.

# The Consequence of Poor Signals

## Lab Noise and Poor Signal Clarity

- Despite the important progress that has been made in the diagnosis and treatment of cardiac arrhythmias over the last 35 years, noise from the lab environment substantially interferes with the conventional system's ability to process and visualize intracardiac signals – resulting in blind spots and loss of relevant data.

## The Toll of Inefficiency

- Signal weakness can introduce misleading information, contributing to greater time spent in expensive lab environments. More stress on patient and physician.



**Poor signal quality**



**Rising cost of care**



**Inefficiencies**



PURE EP™

## Our Solution




With the PURE EP™ Platform, we preserve the value of cardiac signals and deliver clear, actionable insights for today's Electrophysiologists.






# Preserving Full-Spectrum Signal Insights with PURE EP™

## Conventional signal pathway




## PURE EP™ signal pathway




# Cardiac Signal Insights with Unprecedented Clarity & Precision

Conventional system



PURE EP™







# Clinical Data Supports Faster Diagnosis & Economic Value

## PURE EP 2.0 STUDY

### Signal Clarity & Relevance\*

In a multi-center, randomized prospective study, PURE EP™'s signals were compared to conventional recording and mapping systems signals:

 75% of PURE EP™ signals rated superior in quality


 83% of the time, physicians were more confident in differentiating signal components with PURE EP™


 73% of the time, PURE EP™ produced superior, small, fractionated signals of clinical significance

## PURE 2.0 SUB - STUDY

### Improved Workflow, Time Cost Savings\*

To determine the difference in procedural times when comparing ablations guided by PURE EP™'s electrocardiogram (EGM) visualization to the conventional system:

 PURE EP™ led to a mean procedure time reduction of:  
**11.3 minutes**

 Given that the mean cost of operating room time is approximately **\$37 per minute<sup>3</sup>**, PURE EP™ demonstrated potential cost savings of approximately:  
**\$418.10 per procedure**

# Clinical Data Supporting Procedural Accuracy & Ablation Time



Cleveland Clinic researchers presented 3 abstracts at HRS 2023 featuring our PURE EP™ Platform vs. the conventional Ablation Index™

## Abstract 1

*Unipolar Signal Modification-Guided Radiofrequency Ablation*

**Reduced time of ablation by 2/3**  
with real-time, tissue-specific feedback vs. surrogate markers

## Abstract 2

*Feasibility of Unipolar Signal Guided Ablation in Creating Contiguous Lines of Conduction Block: A Proof-of-Concept Study*

**Maintained accuracy in lesion spacing**  
to successfully block arrhythmia-causing electrical impulses

## Abstract 3

*Comparison of Unipolar Electrogram Monitoring during Radiofrequency Ablation in Viable and Ablated Myocardium: Loss of the S-component*

**Enhanced precision in lesion placement**  
by differentiating between healthy and scarred tissue

# Integrating into EP Labs for Improved Efficiency



PUREEP™

“

*Having high-quality, better signals makes a difference in almost every case. Since we installed the system in our lab, the efficiency in which we operate has significantly improved.* ”

**~Dhanunjaya DJ Lakkireddy, MD**

Kansas City Heart Rhythm Institute, Overland Park, KS

*Complex AF Case Study Utilizing a New Standard in Signal Processing*



# PURE EP™ — Commercial History



## Version 7 Software Release

- Impactful clinical software
- 20 mins of time savings\*
- Near Field Tracking (NFT) Algorithm
- 66% reduction in (RF) ablation time

AUGUST 2023



## Subscription Model Early Adoption

- Tiered pricing model
- Revenue generation for hospital
- First customer sales


NOVEMBER 2023



## Reimbursement Code Implementation

- Implementation of current CPT code for use during ablations
- Adds to procedure revenues

DECEMBER 2023



## Market Release + Distribution Partnership

- NFT rollout
- Supportive Clinical data
- Continued Product Upgrades
- Secure distribution partnership.

JANUARY 2024 →



# PURE EP™ - New Novel Software Features



## Automatic Tachycardia Characterization (ATC)

Alerts electrophysiologists to heart conduction patterns that may be difficult to detect with the naked eye or that might warrant further evaluation.



## Near Field Tracking (NFT)

Monitors changes in the local unipolar electrogram to provide real-time tissue feedback that assists electrophysiologists as they make their final determinations between healthy and scarred tissue for lesion placement during an ablation.

“


*Near Field Tracking is a unique algorithm for assessing lesion efficiency and increases my procedural efficiency and confidence . . . This revolutionary feature has become a critical tool during all my complex cases.*”



**Hicham El Masry,**  
MD, FHRP, Cardiac Electrophysiologist  
Mayo Clinic Arizona



# A Strong, Well-Protected Patent Portfolio



# Growing into an Expanding Global Market



**\$1.6  
billion**

total global  
addressable market

**14.4 million  
Americans suffer  
from cardiac  
arrhythmias**

**Atrial Fibrillation** is  
the most common  
arrhythmia affecting:  
~6.1 million people in  
the U.S. and growing  
~33.5 million people  
worldwide

**Catheter ablation  
is fast becoming a  
first-line therapy**

Global ablation  
procedures:  
~1.5 million in 2022  
~8.4% CAGR  
  
Complex ablation  
procedures:  
~13.5% projected  
CAGR

**EP labs  
are growing  
to meet demand**

Estimated:  
~3,425 EP labs in  
U.S.  
  
~3,915 EP labs  
outside the U.S.

# Leading with Strong Industry Experience



**Ken Londoner**

Founder, Chairman,  
Chief Executive Officer,  
Director

---

Endicott Management  
Partners; J & W Seligman  
& Co.; Visiting Professor,  
Columbia University



**Steve Buhaly**

Chief Financial Officer

---

Qorvo; Longview Fibre;  
Planar System



**Fred Hrkac**

Executive Vice President,  
Director

---

Biosense Webster; Boston  
Scientific

# Why BioSig Now?



## Disruptive and novel technology

Our technology saves procedural time and improves workflow efficiency in an environment where the technology has not changed meaningfully in 25+ years.



## Substantial and growing global market

Global EP market is growing by 11.2% and expected to reach \$16B by 2028.



## Strong clinical data pipeline

Published/ongoing clinical studies supporting commercialization.



## Shift to Distribution Partnership

New focus on sourcing distribution partner(s) to support the sales & distribution of PURE EP™.




## Flexible pricing model

Supports recurring revenue and continuous innovation.



## Reimbursement

Addition of CPT code for physician and hospital reimbursement.



## Well-protected IP portfolio

100+ Worldwide fundamental patents granted/allowed.

# Contact us

**Andy Ballou**

VP of Investor Relations [aballou@biosigtech.com](mailto:aballou@biosigtech.com)

203-409-5444, x133

**BioSig Technologies, Inc.**

55 Greens Farms Road

Westport, CT 06880

[www.biosig.com](http://www.biosig.com)